Pulmonary Arterial Hypertension
-
Merryman, Lindsley make headway in drug development to cure pulmonary arterial hypertension
Research led by David Merryman, a professor of biomedical engineering, pharmacology and medicine who holds the Walters Family Chair, has resulted in the development of VU6047534, a new drug that treats pulmonary arterial hypertension—a type of high blood pressure that affects arteries in the lungs and in the heart—without serious neurological side effects. Merryman conducted... Read MoreSep 13, 2023
-
Mitochondrial mutations and disease
New findings suggest that oxidative stress damages mitochondrial DNA, and they link this damage to a disease state. Read MoreFeb 22, 2018
-
Block estrogen to treat lung disease
Based on findings from Vanderbilt investigators and others, clinical trials of estrogen inhibition for pulmonary arterial hypertension have recently been approved and funded by the National Institutes of Health. Read MoreAug 17, 2017
-
Marrow cells’ role in pulmonary hypertension explored
Cells from the bone marrow participate in the development of pulmonary arterial hypertension (PAH), and they can also protect against it, according to new findings from a team of Vanderbilt University Medical Center investigators. Read MoreJul 28, 2016
-
Hypertension hiatus
New findings offer a potential strategy for preventing heritable pulmonary arterial hypertension. Read MoreFeb 23, 2016